Eupraxia Pharmaceuticals Inc.
EPRX
$2.93
-$0.175-5.65%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -25.50M | -28.22M | -27.00M | -30.37M | -28.22M |
| Total Depreciation and Amortization | 171.70K | 158.40K | 159.30K | 155.40K | 155.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.10M | -107.30K | -2.11M | 890.30K | 1.96M |
| Change in Net Operating Assets | -6.76M | -1.82M | 3.21M | 7.02M | 5.35M |
| Cash from Operations | -29.99M | -29.99M | -25.74M | -22.30M | -20.75M |
| Capital Expenditure | -104.20K | -109.30K | -76.60K | -72.10K | -73.40K |
| Sale of Property, Plant, and Equipment | 29.10K | 28.50K | 28.50K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -75.20K | -80.80K | -48.10K | -72.10K | -73.40K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -9.14M | -9.16M | -4.58M | -80.60K | -79.40K |
| Issuance of Common Stock | 54.92M | 23.22M | 39.52M | 44.12M | 21.16M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 45.78M | 14.06M | 34.95M | 44.04M | 21.08M |
| Foreign Exchange rate Adjustments | -1.96M | 107.00K | -264.60K | 315.50K | 821.40K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 13.76M | -15.90M | 8.89M | 21.98M | 1.08M |
